Hu23F2G humanized antibody: Delayed the start of a Phase I study,

Icos Corp. (ICOS), Seattle
Product:

Read the full 53 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE